Posted from: Thursday, April 07, 2016 - 11:18 AM - Present

Generic Nasonex Launched

March 22, 2016 – The Generic Manufacturer, Apotex, announced the launch of its A-rated generic to Nasonex (mometasone furoate monohydrate) by Merck; a corticosteroid primarily used for the treatment of nasal symptoms associated with allergic rhinitis. Although nasal corticosteroids are in the process of transitioning from prescription to over-the-counter, plans and timing for Nasonex to convert from a prescription to an over-the-counter drug are currently unknown.

 Other nasal corticosteroids including Flonase, Nasacort, and Rhinocort Aqua are already in the approval process. Dosage forms available for the newly launched generic include 50mcg of mometasone furoate in each 100 microliter nasal spray. The annual U.S. sale thus far, according to IMS Health is $955.5 million in the period of the most recent 12 months ending in January 2016.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Saturday, December 09, 2017 - 04:40 AM.